Multiple Sclerosis

March 2, 2018

Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis

CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.–(BUSINESS WIRE)–Biogen (Nasdaq:BIIB) and AbbVie (NYSE:ABBV) today announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing multiple sclerosis. The companies believe that characterizing the complex and […]
December 18, 2017

Number of Multiple Sclerosis Patients in US Closer to 1 Million, NMSS Survey Finds

There are more Americans with multiple sclerosis than previously thought. An estimated 947,000 people in the U.S. have multiple sclerosis (MS) — more than double the […]
December 11, 2017

Ozanimod successful in clinical trials for multiple sclerosis

The medication ozanimod is showing good results in studies with multiple sclerosis. The findings from the two pivotal phase 3 (SUNBEAM and RADIANCE Part B) trials […]
November 17, 2017

Multiple Sclerosis Can Stay Mild for Decades, 30-year British Study Shows

Multiple sclerosis can progress very slowly for some patients. After the first round of symptoms, multiple sclerosis can stay mild without causing major problems for decades, a […]
November 13, 2017

Concussions in Teenagers Tied to Multiple Sclerosis Risk 

Head injuries might be linked to future multiple sclerosis risk. Here’s yet another reason to protect young athletes from head trauma: A large-scale new study found […]
November 10, 2017

Relapsing MS Patients Being Recruited to Global Phase 3 Trial of Ponesimod Plus Tecfidera

New study of an MS medication is recruiting for patients. Actelion is recruiting about 600 relapsing multiple sclerosis (MS) patients to a Phase 3 trial testing the […]
February 7, 2017

‘Stunning breakthrough’ helping to rapidly identify types of MS

New diagnostic tests for multiple sclerosis are in the works. Patients with multiple sclerosis will soon have access to a new test which can tell them […]